Current Psychiatry Research and Reviews - Volume 21, Issue 4, 2025
Volume 21, Issue 4, 2025
-
-
Mental Health Issues Among Adolescents: Challenges and Management
More LessAuthors: Saurabh Kumar, Krishan Kumar, Pramod K Avti and Akshay AnandAdolescence is an important stage of life between childhood and adulthood. The shift in lifestyle, physical inactivity, high expectations of family/friends/teachers, and continuous exposure to social media and the internet have created physical, social, emotional, and mental imbalances in adolescents. The individuals of this age group are vulnerable and exposed to these stressful factors, leading to psychological complications. Most psychological problems diagnosed in the later stages of life begin in adolescence. The purpose of this mini-review was to identify mental health problems and available non-pharmacological interventions to manage the overall well-being of adolescents. A literature search was conducted to identify relevant studies, including research, review, and other articles/data available on PubMed, Google Scholar, ScienceDirect, WHO, GHDx, and AACAP. Search keys included essential keywords like adolescence, yoga, mental health, anxiety, depression, and a combination of these words. The literature search identified several mental disorders like emotional, behavioral, identity, psychosis, dietary, and other risky behaviors. Most of the non-pharmacological interventions adopted focused on improving the mental and physical well-being in school and community settings. Among all the interventions, we found yoga to be the most popular and widely accepted effective tool that reduces anxiety, depression, and psychological problems. Yoga also improved resilience, attention, and other well-being parameters. Yoga helps manage physical and mental health in adolescence.
-
-
-
Revolutionizing Psychiatric Care: Unleashing the Potential of Augmented and Virtual Reality for Diagnosis and Education
More LessNew technologies, such as augmented reality (AR), mixed reality (MR), and virtual reality (VR), are not only of interest to gamers but are increasingly being used in health care as well. Visual content is used in everyday life to enhance the user's visual input. Its medicinal uses have been extensively studied. It can be a promising surgical technique that requires considerable accuracy. Furthermore, the emotional engagement and sensation of participation in the AR program impact the level of the customer experience. These experiences may enhance the efficacy of AR in the management of psychiatric problems. This paper presents an overview of AR and reviews the latest medical applications in diagnosing and treating psychiatric disorders. However, it is fair to say that VR systems have easy delivery with well-controlled sensory motives. The prospect of VR systems is that they could be a new clinical tool for patients with certain psychiatric symptoms. Besides the lack of big observational studies and cost-effectiveness research, it appears that physicians will soon adopt this new technology.
-
-
-
Understanding the Bidirectional Relationship between Alzheimer's and Depression
More LessAuthors: Arzoo Pannu and Ramesh K. GoyalWith an ageing global population, understanding the potential links between mental health and neurodegenerative disorders has become increasingly crucial for comprehensive patient care. A comprehensive search of electronic databases yielded a selection of studies encompassing clinical trials, longitudinal cohorts, and cross-sectional analyses, published between 2000 and 2023. Key inclusion criteria focused on investigations involving both Alzheimer's disease and depression, encompassing a range of methodologies, including neuroimaging, epidemiological surveys, and clinical assessments. The analysis reveals compelling evidence of a bidirectional relationship, where depression serves as a potential precursor to Alzheimer's disease, and vice versa. Neurobiological mechanisms, including neuroinflammation, neurotransmitter imbalances, and genetic predispositions, emerge as significant contributors to this complex association. Furthermore, psychosocial factors, such as chronic stress and social isolation, are identified as potential accelerators of cognitive decline in individuals with co-occurring depression and Alzheimer's. Additionally, therapeutic interventions targeting both conditions concurrently exhibit promising outcomes in mitigating cognitive decline and ameliorating depressive symptoms. Approaches encompassing cognitive behavioural therapy, pharmacological interventions, and lifestyle modifications demonstrate potential avenues for integrated treatment strategies. This review underscores the imperative for a multidisciplinary approach to patient care, emphasizing the importance of early detection and intervention for individuals presenting with symptoms of depression and cognitive impairment. Future research avenues should prioritize longitudinal studies with larger cohorts to delineate the causal pathways and further elucidate effective treatment modalities for this intricate comorbidity. By unravelling the complexities of the Alzheimer's-depression nexus, we pave the way for more targeted and comprehensive interventions to improve the lives of those affected by these debilitating conditions.
-
-
-
CNS Delivery Systems Based on Nanotechnology with Particular Attention to Parkinson's and Alzheimer's Disease –A Review
More LessNanotechnology has emerged as a promising frontier in the field of drug delivery, offering unprecedented opportunities for precise and targeted interventions in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases. This review explores recent advancements in nanotechnology-based delivery systems designed to enhance drug transport across the blood-brain barrier and facilitate targeted drug delivery to the central nervous system. The unique challenges posed by the intricate central nervous system architecture, particularly in the context of Parkinson's and Alzheimer's diseases, necessitate innovative solutions to improve therapeutic outcomes. The review comprehensively discusses various nanocarrier platforms, including liposomes, polymeric nanoparticles, dendrimers, and exosomes, and their potential applications in drug delivery to the central nervous system (CNS). Special emphasis is placed on addressing the multifaceted challenges associated with neurodegenerative diseases, such as the need for sustained drug release, protection of therapeutic agents from enzymatic degradation, and the efficient crossing of the blood-brain barrier. Furthermore, the review highlights recent breakthroughs in nanotechnology-driven diagnostic and therapeutic approaches, ranging from early detection of disease biomarkers to the targeted delivery of neuroprotective agents. The potential of personalized medicine and the integration of advanced imaging techniques with nanotechnology for precise disease monitoring are also discussed. In conclusion, this review provides a comprehensive overview of recent advancements in nanotechnology-based delivery systems tailored for CNS targeting, with a specific focus on Parkinson's and Alzheimer's diseases. The synthesis of current research findings underscores the transformative potential of nanotechnology in reshaping the landscape of therapeutic strategies for neurodegenerative disorders, offering hope for improved patient outcomes and the development of novel treatment modalities.
-
-
-
Unveiling the Therapeutic Potential of Modern Probiotics in Addressing Neurodegenerative Disorders: A Comprehensive Exploration, Review and Future Perspectives on Intervention Strategies
More LessAuthors: Himanshu Sharma, Rashmi Pathak and Deepak BiswasThe continual deterioration of the structure and function of the nervous system is a major global health problem associated with neurodegenerative disorders. Gut-brain axis plays a significant role in linking gut microbiota to neurological function. Live microorganisms that benefit the host's health are called probiotics. These probiotics are increasingly recognized as beneficial for treating neurodegenerative diseases. This review investigates the impact of probiotics on neurodegenerative disorders, specifically focusing on conditions like Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. According to studies, probiotics have the power to alter the host's neuroimmune response, lower inflammation, and modify the composition of the gut microbiota. Studies have indicated a potential relationship between the stomach and the brain by connecting variations in the gut microbiota to neurodegenerative diseases. Probiotics can influence the gut flora, which leads to a reduction in neuroinflammation, oxidative stress, and other pathological processes linked with these conditions. This review also discusses how probiotics impact the central nervous system through mechanisms such as altered blood-brain barrier function, neurotrophic factor regulation, and neurotransmitter production. Based on preclinical and clinical data, probiotics are also highlighted as an adjunctive or prophylactic treatment for neurodegenerative diseases. More research is needed to find the exact strains, dosages, and duration of probiotic therapies required to have the greatest neuroprotective effects, despite the good results thus far. It is also acknowledged that translating findings from animal studies to human applications can be challenging. With the ability to reduce the neuropathological features of Parkinson's and Alzheimer's diseases, probiotics provide a novel therapeutic approach for neurodegenerative illnesses.
-
-
-
The Social Media Mirror: Understanding the Distortion of Eating Habits and Body Image in the Digital Age
More LessThe influence of media on body image and the development of eating disorders (EDs) has gained increasing attention in contemporary society. This article offers a comprehensive exploration of the intricate relationship between media exposure, body dissatisfaction, and disordered eating behaviors. We commence by elucidating the foundational concepts of body image, EDs, and positive body image, underlining their significance for both mental and physical well-being. The three most common EDs: anorexia nervosa, bulimia nervosa, and binge eating disorder (BED), provide an overview of their distinct characteristics. The article delves into the profound impact of media in shaping contemporary beauty ideals and propagating unrealistic body expectations. The cause-and-effect relationship between media messages and body dissatisfaction, with specific attention to the prevalence of this issue among females in Western cultures has been covered. Furthermore, we explore the potential predisposing factors associated with media exposure that contribute to the development of EDs. This review highlights the critical role of media literacy education in empowering individuals to critically analyse and interpret media content, enabling them to make informed decisions about their media consumption. In addition, an attempt has been made to provide insights into the future of media and its impact on body image, emphasizing the need for ongoing research to better understand the evolving media landscape. Educators are recognized as pivotal in nurturing healthy body image among students, and school-based interventions can significantly contribute to promoting self-esteem, positive body image, and healthy lifestyle choices.
-
-
-
The Impact of Community-based Mental Health Interventions on Mental Disorders
More LessIntroductionCommon Mental Disorders (CMD) cause significant impairment in socio-occupational functioning, leading to dreadful socio-economic consequences on the individual, family, and society. Even though mental illness is prevalent worldwide, the public health burden of mental illness seems to be the highest in low- and middle-income countries (LMICs). In these countries, lack of access to essential mental health services has also led to a significant treatment gap in psychiatric disorders. In such a situation, reaching out to the community and utilizing community-based resources to decentralize mental health care is essential.
ObjectiveThe aim of this narrative review was to appraise the impact of community-based mental health interventions on CMD. This review also highlights the impact of the rights-based approach in mental health care and the psychosocial determinants of mental health.
MethodsA thorough search of databases, such as PubMed/Medline, CINHAL, and Scopus, was done to gather articles published between January 2001 and July 2023. Studies answering the central theme of the review, such as the trends and existing mental health services in the community and their impact on CMD, were included in the review. The relevant articles were analyzed in detail.
ResultsInvolvement of people at the grassroots level through peer support programs or in recovery camps, addressing the social determinants like poverty, housing, and unemployment, and a rights-based approach in every mental health service were found to be beneficial and effective in running community mental health services. These approaches are the need of the hour and are well accepted by the people in the community.
ConclusionIn order to overcome the treatment gap in LMICs, a well-utilized community mental health service is the only way out. The allocation of adequate funds by policymakers, the development of infrastructure, and investment in manpower need to be scaled up tremendously.
-
-
-
The Efficacy of Bibliotherapy in Depression Management: A Systematic Review of Randomized Clinical Trials
More LessAuthors: Arzoo Pannu, Ramesh K. Goyal and Kalicharan SharmaAimThis systematic review critically evaluates the efficacy of bibliotherapy in addressing mental health concerns across various populations and intervention modalities.
MethodsA comprehensive bibliographic search was conducted, identifying 20 articles from databases PubMed, Scopus, and Google Scholar, representing studies published in English between 1990 and 2022. The selected randomized clinical trials were subjected to rigorous evaluation using Cochrane's Risk of Bias tool to assess methodological quality. Inclusion criteria focused on RCTs examining bibliotherapy programs for depression treatment. The selected studies were analyzed based on their comparison of bibliotherapy outcomes with standard treatments or no intervention. Follow-up periods ranging from 2 weeks to 3 years were considered.
ResultsOut of 413 retrieved results, 20 articles were included, reporting 3354 subjects. The methodological quality of the studies, assessed using Cochrane's Risk of Bias tool, was found to be sound. Bibliotherapy demonstrated significant improvements in depressive symptoms in older patients as studied in 3 long-term bibliotherapy RCTs and 7 short-term bibliotherapy RCTs. In young patients, 3 long-term bibliotherapy RCTs have shown significant improvement in depressive symptoms over 6 months to 2 years, whereas 7 short-term bibliotherapy RCTs also showed significant improvement within a brief timeframe. The review explores bibliotherapy's efficacy in managing occupational stress and its potential as a therapy for depression in populations with chronic physical illnesses.
ConclusionThe findings imply that bibliotherapy could serve as an affordable and prompt intervention, potentially reducing the need for additional medications. However, the study emphasizes the importance of further research to strengthen the evidence base, particularly in diverse populations and settings.
-
-
-
The Effect of Haptonomy on Fear of Childbirth and Maternal-fetal Attachment: A Systematic Review and Meta-analysis
More LessAuthors: Zahra Alivand, Roghaiyeh Nourizadeh, Sevil Hakimi, Khalil Esmaeilpour and Esmat MehrabiBackgroundHaptonomy is considered one of the non-pharmacological interventions in reducing Fear of Childbirth (FOC) and increasing Maternal Fetal Attachment (MFA). No review study has been conducted for an evidence-based conclusion in this regard.
ObjectiveThis study aimed to evaluate the pooled effect of haptonomy on FOC and MFA.
MethodsA systematic literature search was conducted in an electronic database (Scopus, Cochrane Library, ClinicalTrials.gov, Embase, ProQuest, PubMed, Google Scholar, Web of Science, SID, and Magiran) until January 30th, 2023, to find all interventional studies that reported the effect of haptonomy on FOC and MFA.
ResultsA total of 26 relevant articles were retrieved in the search, of which 4 articles were included in the systematic review. Meta-analysis was conducted for three research studies with the outcome of FOC and three studies with the outcome of MFA. The meta-analysis of three research conducted on 239 participants indicated the positive effect of hatonomy intervention on reducing FOC (MD: -22.91; 95% CI: -28.21 to -17.61; p < .001), and owing to the moderate heterogeneity, the random effect model was used (I2 = 41.38%). The results of the meta-analysis of three research with 286 participants indicated the ineffectiveness of haptonomy intervention on the MFA (MD: 4.35; 95% CI: -2.72 to 11.42; p = .23) (I2 = 59.95%).
ConclusionHaptonomy intervention during pregnancy reduces FOC without playing any role in increasing MFA. However, conducting the clinical trials with a larger sample size by means of standard tools is recommended due to the limited number of haptonomy interventions on MFA and the moderate heterogeneity of reviewed studies.
-
-
-
Anxiety and Depression Predicted Quality of Life during Menopause
More LessBackgroundDepression and anxiety are common during menopause and may affect the quality of life (QoL) during menopause.
ObjectiveThis study aims to assess the potential predictivity of depression and anxiety with quality of life (QoL) during the postmenopausal period.
MethodsThis was a cross-sectional study on 285 postmenopausal women in Tehran- Iran. Quota sampling was used to recruit eligible women from health centers in Tehran. The tools for data collection were four questionnaires: demographic, WHQOL-BREF, Beck depression, and Speilberger questionnaires. Data were analyzed using SPSS-V23 by conducting Pearson correlation and multiple linear regression.
ResultsThe average age and duration of menopause of the participants were 55.10±3.91 years old (Mean±SD) and 5.90±4.38 years, respectively. Mild to severe anxiety and depression were found among 84.6 and 55.8 percent of the participants, respectively. There was a negative and significant correlation between QoL and all its dimensions with depression and anxiety scores (p < 0.001). There was a significant correlation between QoL and the education level of the woman and her husband, income sufficiency, the number of children, and housing status (p < 0.001). Multiple linear regression model showed QoL is predicted by anxiety (B=-0.82, p < 0.001) and depression (B=-0.47, p < 0.001) as well as income sufficiency (B=2.26, p < 0.001) and husband’s educational level (B=1.87, p < 0.017) during menopause.
ConclusionDepression and anxiety are common complications during menopause that affect the womens QoL. Therefore, the promotion of psychological health to reduce depression and anxiety should be considered for future health plans for improving QoL during menopause.
-
- Medicine, Psychiatry
-
-
-
Efficacy of Nano-curcumin Supplementation on Depression, Anxiety, Stress and Clinical Symptoms in Migraine Patients: A Randomized Double-blind Clinical Trial
More LessBackgroundMigraine is a debilitating neuroinflammatory disorder. Patients with migraine often experience elevated levels of depression, anxiety, and stress, which are associated with the frequency and severity of migraine attacks. Curcumin has been shown to have regulatory effects on depression, anxiety, and stress, as well as analgesic properties through various mechanisms. The objective of this study was to assess the impact of nano-curcumin supplementation on depression, anxiety, stress, and clinical manifestations in patients with migraine.
MethodologyThis study was conducted as a randomized, double-blind clinical trial. A total of forty-four patients with episodic migraines were recruited for the trial. Stratified randomization was employed to ensure a balanced distribution of participants based on BMI and sex. The patients were equally assigned to two groups using permuted block randomization: 1) the intervention group, which received 80 mg of nano-curcumin, and 2) the placebo (control) group, which received a paraffin-based placebo. The intervention and control periods lasted for 2 months. Anthropometric and demographic data, clinical signs and symptoms (including headache frequency, duration, and severity as reported by the patients), as well as stress, anxiety, and depression scores (using the Dass-21 questionnaire), were recorded before and after the study. The collected data were analyzed using SPSS 22. For normally distributed data, paired t-tests and independent t-tests were utilized. Non-normal data were analyzed using the Wilcoxon test and Mann-Whitney U test. The chi-squared test was employed for categorical variables. To account for confounding factors, the ANCOVA test was conducted. A p-value of ≤ 0.05 was considered statistically significant. The intention-to-treat method was applied to address outliers and missing data.
ResultsBased on the findings, the current study demonstrates that supplementation with nano-curcumin can effectively mitigate symptoms of depression and anxiety (p < 0.05). Regarding stress, a noticeable reduction within the nano-curcumin group was observed, although it did not reach statistical significance when compared between groups (p > 0.05). Moreover, nano-curcumin exhibited a significant decrease in the frequency, duration, and severity of headaches (p < 0.05).
ConclusionOur research findings have shown that supplementation with nano-curcumin can effectively decrease the frequency, severity, and duration of headaches while also alleviating symptoms of depression and anxiety in comparison to the placebo group. Hence, curcumin exhibits significant potential as an adjuvant therapy to enhance the treatment of migraines.
Clinical Trial Registration NumberIRCT20160626028637N2.
-
-
-
-
Safety and Efficacy of Mirtazapine Compared to Sertraline in Hemodialysis Patients with Major Depressive Disorder: A Randomized Controlled Clinical Trial
More LessBackgroundThis study aimed to compare the efficacy and tolerability of mirtazapine and sertraline in moderately depressed patients undergoing chronic hemodialysis therapy.
MethodsIn this double-blind clinical study, 54 hemodialysis patients diagnosed with moderate to severe depression, scoring greater than 18 on the Beck Depression Inventory, version II (BDI-II), were randomly assigned to receive 12 weeks of treatment with either mirtazapine (15mg/day) plus placebo or sertraline (50 mg/day) plus placebo. Efficacy outcomes were assessed by evaluating changes in baseline BDI-II scores, as well as rates of response and remission at weeks 2, 4, 8, and 12 of treatment. The impact of the antidepressant treatment on the patient’s health-related quality of life was also assessed at the end of the treatment phase, with ratings ranging from 0 (the worst impact) to 10 (the best impact). Safety and tolerability of the study medications were monitored using an antidepressant side effect checklist and through spontaneous participant reports. Both efficacy and tolerability analyses were conducted on the intent-to-treat sample. The p-values less than 0.01 based on Bonferroni's multiple-testing correction method were considered statistically significant.
ResultsThe mixed models for repeated measures analysis revealed a significant time effect on depression symptoms (p < 0.001), indicating improvement in both treatment groups over the study period. However, the treatment effect was not significant (p = 0.160), suggesting no overall difference in depressive symptoms between groups. The interaction between time and treatment was significant (p = 0.020), indicating varying changes in depressive symptoms over time between treatment groups. At week two, patients receiving mirtazapine had a lower mean BDI-II score than those receiving sertraline (15.62±5.24 versus 18.92±5.03), but the difference between the groups was not statistically significant (p-value = 0.022). Subsequent assessments at weeks 4, 8, and 12 showed comparable mean BDI-II scores between both treatment groups. Furthermore, at all assessment points, the rate of responders (≥50% reduction in BDI-II total score from baseline) and the rate of remitters (BDI-II total score of <10) were similar between the treatment groups. However, mirtazapine-treated patients scored higher in assessing the overall impact of the treatment on their quality of life compared to the sertraline-treated group (7.40±1.18 versus 6.51±1.15 p-value = 0.007). Regarding safety and tolerability, although there were differences in the pattern of adverse effects between the treatment groups, the proportion of patients experiencing at least one adverse effect and the rate of dropouts were similar between the two groups, indicating comparable tolerability for both medications.
ConclusionOur results suggest that the efficacy and tolerability of mirtazapine are equivalent to those of sertraline in treating moderate depression in hemodialysis patients. However, mirtazapine appears to have a more favorable effect on patients' health-related quality of life compared to sertraline.
Trial RegistrationThe trial was registered at the Iranian Registry of Clinical Trials (https://www.irct.ir/trial/66756, identifier code: IRCT20120215009014N445). Registration date: 2022-11-09.
-
Most Read This Month